Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 2003

View Archived Issues

Benzimidazole CDK4 inhibitors under study at Aventis

Merck scientists present a novel GABA-A agonist for use in anxiety and convulsions

Fuji Photo Film claims new contrast agents for the diagnosis of vascular disorders

New HIV protease inhibitors in early development at BMS

Pfizer patent covers novel thyroid receptor ligands and their use

Dithiazole-based MMP inhibitors newly discovered at Shiseido

Vitamin E analogue sensitizes Jurkat cells by suppressing NF-kB activation

Restructuring update at CeNeS

Arava approved for rheumatoid arthritis in Japan

Ketek may exacerbate symptoms of myasthenia gravis

Vilazodone results fail to support progression to phase III

Northwest Biotherapeutics receives NCI grant for tumor growth inhibition

Nastech reacquires intranasal apomorphine rights following Pfizer-Pharmacia merger

DynPort completes smallpox vaccine phase I trial

Patient treatment begins in phase I trial of VIT-100

Phase II studies of ILX-651 planned

Virulizin phase III trial extended to Canada and Mexico

Ribozyme changes name

AGI Dermatics regains rights to Dimericine

Novo Nordisk and Fournier sign repaglinide comarketing deal for Europe

Vasopeptidase inhibitor as effective as ACE inhibitor in old SHR

Tricyclic bis-enone compounds as inhibitors of NO production

Profile of SLV-310, a potential antipsychotic agent

5-HT6 receptor-selective antagonist reverses cognitive deficits in animal model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...